These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 35890211)

  • 1. Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation.
    Tang X; Wang Z; Hu S; Zhou B
    Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.
    Rana P; Anson B; Engle S; Will Y
    Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling drug-induced mitochondrial toxicity with human primary cardiomyocytes.
    Tang X; Liu H; Rao R; Huang Y; Dong M; Xu M; Feng S; Shi X; Wang L; Wang Z; Zhou B
    Sci China Life Sci; 2024 Feb; 67(2):301-319. PubMed ID: 37864082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
    Clements M; Millar V; Williams AS; Kalinka S
    Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
    Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
    Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
    Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
    Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of mitochondrial toxicity testing in drug development.
    Dykens JA; Will Y
    Drug Discov Today; 2007 Sep; 12(17-18):777-85. PubMed ID: 17826691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes.
    Tertoolen LGJ; Braam SR; van Meer BJ; Passier R; Mummery CL
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1135-1141. PubMed ID: 28153730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.
    Abi-Gerges N; Miller PE; Ghetti A
    Curr Pharm Biotechnol; 2020; 21(9):787-806. PubMed ID: 31820682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
    Yang B; Papoian T
    J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
    Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
    Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening, verification, and analysis of biomarkers for drug-induced cardiac toxicity in vitro based on RTCA coupled with PCR Array technology.
    Zhang L; Xu MX; Yin QS; Zhu CY; Cheng XL; Ren YR; Zhuang PW; Zhang YJ
    Toxicol Lett; 2017 Feb; 268():17-25. PubMed ID: 28099878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
    Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
    Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies.
    Kim CW; Choi KC
    Life Sci; 2021 Jul; 277():119607. PubMed ID: 33992675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving reliability and reducing costs of cardiotoxicity assessments using laser-induced cell poration on microelectrode arrays.
    Iachetta G; Colistra N; Melle G; Deleye L; Tantussi F; De Angelis F; Dipalo M
    Toxicol Appl Pharmacol; 2021 May; 418():115480. PubMed ID: 33689843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.